2.33 +0.06 (2.64%)
After hours: 7:57PM EDT
|Bid||2.27 x 1000|
|Ask||2.41 x 900|
|Day's Range||2.11 - 2.37|
|52 Week Range||1.86 - 3.59|
|Beta (3Y Monthly)||1.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
AVEO Oncology (AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma. The results were presented today at European Society of Medical Oncology (ESMO) 2018 Annual Congress, in a poster presentation titled “TiNivo: Tivozanib Combined with Nivolumab: Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma (mRCC)” (Presentation 878P).
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
AVEO Oncology (AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA®) in combination with intravenous nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January, is available via the ESMO 2018 Annual Congress website.
AVEO Oncology (AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA. The TIVO-3 trial is the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The Company expects to complete data analysis and report topline results from the study in approximately 6 weeks.
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...
Hint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.
A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When a biotech company prices a common stock offering, diluting existing shareholders, the stock typically falls. Around $11.1 million of its net income is due to a non-cash gain related to the fall in the fair value of the 2016 private placement warrant liability.
A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
NEW YORK, NY / ACCESSWIRE / August 27, 2018 / U.S. equities closed up on Friday following Federal Reserve Chairman Jerome Powell's speech, which confirmed the Federal Reserve will gradually normalize monetary ...
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teradata ...
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of common stock on the same terms and conditions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab).
AVEO Oncology (AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. CANbridge licensed worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 from AVEO and AVEO is eligible to receive up to $40 million in potential additional development and regulatory milestone payments and up to $90 million in potential commercial milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.
AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results did not meet Wall Street expectations. ...